[4]. Kamada T,Togashi Y, Tay C, et al. PD-1+ regulatory T cells amplified by PD-1 blockadepromote hyperprogression of cancer[J]. Proceedings of the National Academy ofSciences, 2019, 116(20): 9999-10008.[5]. Adeegbe D O, NishikawaH. Natural and induced T regulatory cells in cance...
7. T. Kamada, Y. Togashi, C. Tay, D. Ha, A. Sasaki, Y. Nakamura, E. Sato, S. Fukuoka, Y. Tada, A. Tanaka, H. Morikawa, A. Kawazoe, T. Kinoshita, K. Shitara, S. Sakaguchi, H. Nishikawa, PD- 1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of c...
一方面,GBM细胞可以分泌各种"促肿瘤"的生长因子或化学因子,从而影响巨噬细胞的极化、促进调节性T细胞(regulatory T cells,Tregs)的募集、抑制树突细胞(dendritic cell,DCs)和自然杀伤(natural killer,NK)细胞的功能等;另一方面,GBM细胞可以通过自身表达免疫抑制性分子,如程序性死亡因子1(programmed death 1,PD-1)的配...
2022年1月27日，日本国立癌症研究中心Hiroyoshi Nishikawa教授领衔在Cancer Cell杂志发表了题为Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments的研究长文，通过从代谢角度研究TME中表达PD-1的效应T细胞和Treg细胞间稳态平衡的影响因素，发现乳酸能够作为Treg细胞的...
另外,负责维持正常体液免疫稳态的主要是滤泡调节性T细胞(follicular regulatory T cells, TFR)。TFR主要来源于Treg的分化,能够负向调控体液免疫的中心轴“TFR-B细胞-抗体”,防止抗体介导的自身免疫性疾病发生。与之功能相反的则是滤泡辅...
2.Kumagai, S. et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell 0, (2022). 3. Schmidl, C., Hansmann, L., Blood, T. L.-, Journal, T. & 2014, undefined...
Basic Information英文标题:Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer中文标题:对比细胞毒性T细胞和调节…
Background AMP-activated protein kinase (AMPK) is a metabolic sensor that maintains energy homeostasis. AMPK functions as a tumor suppressor in different cancers; however, its role in regulating antitumor immunity, particularly the function of regulatory T cells (Tregs), is poorly defined. Methods ...
此外,TILs中的PD-1+Treg细胞可以作为临床治疗的靶点,进一步研究后或许可以进行临床应用。 参考资料: [1] The PD-1 expression balance between effector and regulatory T cells predicts theclinical efficacy of PD-1 blockade therapies.
+regulatory T (Treg) cells in the tumor microenvironment can predict the clinical efficacy of programmed cell death protein 1 (PD-1) blockade therapies and is superior to other predictors, including PD ligand 1 (PD-L1) expression or tumor mutational burden. PD-1 expression by CD8+T cells ...